Rosetta Grants Prometheus Rights to Sell Suite of microRNA Diagnostics in US

In doing so, Rosetta is meeting its objective of finding commercialization partners for its existing products as it shifts its focus onto tests that screen for, rather than diagnose, disease.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.